临床IA期≤2cm伴STAS肺鳞癌:肺叶切除优于亚肺叶切除
多中心回顾性研究纳入870例临床IA期STAS阳性肺鳞癌患者,经倾向性评分匹配后比较肺叶与亚肺叶切除的长期生存。肺叶切除显著改善总生存和无复发生存,并降低术后死亡率和复发率。亚组分析显示获益主要体现在年龄<70岁和临床IA2亚组。
要点
- 临床IA期STAS阳性肺鳞癌,肺叶切除的总生存和无复发生存均优于亚肺叶切除。
- 肺叶切除术后死亡率和复发率均低于亚肺叶切除。
- 年龄<70岁和临床IA2患者从肺叶切除中生存获益更明显。
核心结论
- 对于临床IA期STAS阳性肺鳞癌,肺叶切除的生存结局优于亚肺叶切除,可能应作为高度怀疑STAS患者的首选。
- 肺叶切除的预后获益可能因年龄和临床分期而异。
研究设计与样本
- 多中心回顾性研究,纳入2010至2020年中国5个城市7家高容量机构连续收治的临床IA期STAS阳性肺鳞癌手术患者。
- 共纳入870例,倾向性评分匹配后肺叶组476例、亚肺叶组238例。
- 主要终点为总生存,次要终点为无复发生存。
主要发现
- 亚组分析显示肺叶切除在年龄<70岁和临床IA2亚组中生存优于亚肺叶切除,而年龄≥70岁和临床IA1亚组两种术式生存相当。
临床怎么用
- 临床IA期肺鳞癌术前高度怀疑STAS时,可优先考虑肺叶切除以改善生存。
- 对年龄<70岁或临床IA2的STAS阳性患者,肺叶切除的生存优势更明显。
- 对年龄≥70岁或临床IA1的STAS阳性患者,亚肺叶切除的生存结局与肺叶切除相当。
局限性
- 本研究为回顾性设计,即使采用倾向性评分匹配仍可能存在选择偏倚。
- 亚组分析结果需谨慎解读,可能受样本量和事件数限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The efficacy of sub-lobectomy for clinical IA (tumours ≤2 cm) lung squamous cell carcinoma with tumour spread through air spaces (STAS) remains unknown. This study compares long-term survival outcomes between sub-lobectomy and lobectomy, aiming to offer pivotal evidence for optimizing resection strategies for clinical IA STAS-positive squamous cell carcinoma patients. METHODS: Consecutive clinical IA STAS-positive squamous cell carcinoma patients undergoing surgery between 2010 and 2020 at 7 high-volume institutions across 5 Chinese cities were retrospectively reviewed. The primary end-point was overall survival, and the secondary end-point was recurrence-free survival. Propensity-score matching was employed to mitigate selection bias. RESULTS: A total of 870 patients were included, and propensity-score matching yielded 476 and 238 cases in the lobe and sub-lobe groups, respectively. Over an estimated median follow-up of 6.51 years, lobectomy significantly improved overall survival (hazard ratio [95% confidence interval] = 0.598 [0.447-0.761], P < .001) and recurrence-free survival (hazard ratio [95% confidence interval] = 0.572 [0.449-0.733], P < .001), and reduced postoperative mortality (30.7% vs 40.3%, P = .010) and recurrence (39.3% vs 55.0%, P < .001) incidences compared to sub-lobectomy. Further subgroup analysis revealed that lobectomy improved survival outcomes over sub-lobectomy in younger (age <70 years) and clinical IA2 sub-cohorts, while the 2 approaches yielded comparable survival outcomes for elderly (age ≥70 years) and clinical IA1 sub-cohorts. CONCLUSIONS: Lobectomy improved survival outcomes over sub-lobectomy for clinical IA STAS-positive squamous cell carcinoma and thus might be preferred for clinical IA squamous cell carcinoma patients with highly suspected STAS. The prognostic benefits of lobectomy may be discriminated by age and clinical stage.
引用
- Pan H, Chen H, Ge Z, et al. Lobectomy Versus Sub-lobectomy for Clinical Stage IA (≤2 cm) Lung Squamous Cell Carcinoma with Tumour Spread through Air Spaces: A Multi-Centre Retrospective Study. Eur J Cardiothorac Surg. 2025. PMID: 40608486. doi:10.1093/ejcts/ezaf224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。